Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options to acquire 1,684,220 shares of common stock as an employment inducement for newly hired employees. The options were issued on April 19, 2023, at an exercise price of $2.49 per share, equal to the stock's closing price that day. Of the total, 1,586,000 options have a 10-year term and vest over four years, with an initial 12.5% vesting after six months. The remaining shares will vest monthly over the following 42 months. The remaining 98,220 options will vest upon achieving specific regulatory milestones. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and follows Geron’s 2018 Inducement Award Plan.
Geron focuses on therapies for hematologic malignancies, particularly its investigational telomerase inhibitor, imetelstat.
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that John A. Scarlett, M.D., the Chairman and CEO, will participate in fireside chats at two upcoming investor conferences.
- 22nd Annual Needham Virtual Healthcare Conference
Date: April 20, 2023
Time: 10:15 a.m. ET - Stifel 2023 Virtual Targeted Oncology Days
Date: April 25, 2023
Time: 2:00 p.m. ET
Webcasts of the chats will be accessible via the Investor Relations section of Geron’s website and archived for 30 days post-event. Geron is advancing its first-in-class telomerase inhibitor, imetelstat, which aims to impact the treatment of these diseases significantly.
Geron Corporation (Nasdaq: GERN) announced the granting of non-statutory stock options for 490,630 shares of its common stock as an inducement to newly hired employees. These options were issued on
Geron Corporation (Nasdaq: GERN) provided updates on its lead product, imetelstat, and its financial performance for Q4 2022 and the full year. The company reported a net loss of $42.6 million for Q4 and $141.9 million for the year, with revenues of $103,000 and $596,000, respectively. In January 2023, Geron raised $213.3 million through an underwritten public offering. Positive Phase 3 results for imetelstat in lower-risk myelodysplastic syndromes (MDS) have set the stage for planned NDA and MAA submissions in 2023, with potential U.S. commercial launch expected in 2024. The company also intends to grow its workforce to support these initiatives.
Geron Corporation (Nasdaq: GERN) announced it will release its Q4 and full-year 2022 financial results post-market on March 16, 2023. A conference call will follow at 4:30 p.m. ET to discuss these results and future milestones. The press release will be accessible on their website.
Geron is focused on developing therapies for hematologic malignancies with its investigational telomerase inhibitor, imetelstat, which aims to change the course of these diseases.
Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 640,550 shares of common stock to new employees. The stock options were issued on February 15, 2023, at an exercise price of $2.69 per share, matching Geron's closing price on that date. Of the options, 595,800 shares will vest over four years, while 44,750 shares are contingent on achieving specific regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The company focuses on therapies for hematologic malignancies.
Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options to a newly hired employee, totaling 75,730 shares. The options were issued on January 18, 2023, at an exercise price of $3.12 per share, matching the stock's closing price on the grant date. Of these, 70,000 shares have a 10-year term, vesting over four years with an initial 12.5% vesting at six months. The remaining 5,730 shares vest upon achieving certain regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron’s 2018 Inducement Award Plan.
Geron Corporation (Nasdaq: GERN) announced that Dr. John A. Scarlett, Chairman and CEO, will participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET. A live webcast will be available via the Investor Relations section of Geron's website, with an archived replay accessible for 30 days post-event. Geron is focused on developing therapies for hematologic malignancies, including the first-in-class telomerase inhibitor, imetelstat.
Geron Corporation (NASDAQ: GERN) announced key additions to its senior commercial leadership team as it prepares for the anticipated launch of imetelstat, a first-in-class telomerase inhibitor, in the U.S. for lower risk myelodysplastic syndromes (MDS) in the first half of 2024, pending regulatory approvals. The company reported positive Phase 3 clinical trial results and plans to submit a New Drug Application (NDA) in mid-2023 and a Marketing Authorization Application (MAA) in the EU in late 2023. This strategic hiring aims to ensure successful market access and commercialization efforts.
Geron Corporation (NASDAQ: GERN) has successfully completed a public offering of common stock and pre-funded warrants, generating $227.8 million in gross proceeds. The offering included 68,007,741 shares at a price of $2.45 per share, with an additional 25,000,000 pre-funded warrants. After expenses, the net proceeds are estimated to be around $213.3 million. Geron plans to utilize these funds primarily for the potential commercial launch of imetelstat in the U.S. for lower risk MDS and for general corporate purposes.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
